Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kanagawa
Clinical trial register · Japan

Clinical Trials in Kanagawa, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
GlaxoSmithKline24 Hoffmann-La Roche16 Novo Nordisk A/S9 Janssen Research & Development, LLC7 Gilead Sciences3
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Kanagawa

106 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Chiba-shi, Chiba, Fuchu-shi,Tokyo, Fukuoka, Himeji-shi, Hyogo, Hyōgo, Kanagawa, Kumamoto-shi, Kumamoto, Kyoto-shi, Kyoto
2026-10-26
Recruiting
GlaxoSmithKline
Phase 3
800
Ehime, Fukuoka, Gifu, Hokkaido, Kanagawa, Osaka, Tokyo, Toyama
2026-07-27
Recruiting
Kowa Company, Ltd.
Phase 4
120
Hokkaido, Ibaraki, Kagawa, Kanagawa, Osaka, Saitama, Tokyo
2026-07-01
Active, closed
GlaxoSmithKline
Phase 3
102
Aichi, Chiba, Fukui, Fukuoka, Fukushima, Hokkaido, Kanagawa, Kyoto
2026-06-29
Recruiting
ViiV Healthcare
Phase 3
564
Aichi, Kanagawa, Osaka, Tokyo
2026-06-25
Recruiting
Taiho Pharmaceutical Co., Ltd.
Phase 3
784
Aichi, Fukuoka, Hokkaido, Kanagawa, Miyagi, Osaka, Tokyo, Toyama
2026-06-24
Recruiting
GlaxoSmithKline
Phase 3
450
Fukuoka, Hokkaido, Hyōgo, Kanagawa, Mie, Okinawa, Osaka, Saitama
2026-06-18
Recruiting
GlaxoSmithKline
Phase 3
600
Aichi, Fukuoka, Hokkaido, Hyōgo, Kanagawa, Kyoto, Mie, Numakunai
2026-06-04
Recruiting
Kyowa Kirin Co., Ltd.
Phase 2
6
Chiba, Gifu, Hyōgo, Ibaraki, Kagoshima, Kanagawa, Kyoto, Miyagi
2026-04-23
Recruiting
Takeda
Phase 2
42
Tokyo, Fukui, Hiroshima, Kanagawa, Fukuoka, Hyōgo, Yamanashi, Ehime
2026-04-22
Active, closed
Ipsen
Phase 1
6
Kanagawa, Kobe, Kyoto, Osaka, Tokyo
2026-03-10
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Kashiwa, Koto-Ku, Chiba, Fukuoka, Kanagawa, Osaka, Tokyo, Wakayama
2026-03-09
Recruiting
ViiV Healthcare
Phase 2
186
Fukuoka, Kanagawa, Okinawa, Osaka, Tokyo
2026-02-11
Recruiting
GlaxoSmithKline
Phase 3
450
Chiba, Ehime, Fukuoka, Hokkaido, Kanagawa, Kumamoto, Miyagi, Osaka
2025-12-03
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Ichikawa, Kagoshima, Kanagawa, Nagoya, Osaka, Sakai, Sapporo
2025-11-24
Recruiting
GlaxoSmithKline
Phase 2
363
Toyonaka-Shi, Aichi, Fukuoka, Hyōgo, Ibaraki, Ishikawa, Kanagawa, Mie
2025-10-30
Recruiting
Navitor Japan Study
NCT07193888Severe Aortic Stenosis
Abbott Medical Devices
Observational
100
Fukuoka, Kanagawa, Osaka
2025-10-30
Recruiting
GlaxoSmithKline
Phase 3
1,200
Gifu, Kanagawa, Kyoto, Musashino, Yokohama
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Aichi, Fukuoka, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Miyagi, Niigata
2025-10-24
Recruiting
GlaxoSmithKline
Phase 3
420
Fukuoka, Hokkaido, Ishikawa, Kagoshima, Kanagawa, Kochi, Kyoto, Mie
2025-08-11
Recruiting
Daiichi Sankyo
Phase 1
76
Chiba, Kanagawa, Tokyo
2025-07-17
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Aichi, Hiroshima, Hyōgo, Kagawa, Kanagawa, Kochi, Kyoto, Meguro-Ku
2025-07-02
Recruiting
Novo Nordisk A/S
Phase 2
200
Bunkyo-ku, Tokyo, Hamamatsu-shi, Shizuoka, Himeji-shi, Hyogo, Ibaraki, Kanagawa, Kita-gun, Kagawa, Kobe-shi, Hyogo, Osaka
2025-06-30
Recruiting
Novo Nordisk A/S
Phase 2
200
Bunkyo-ku, Tokyo, Chikushino-shi, Fukuoka, Himeji-shi, Hyogo, Ibaraki, Kagawa, Kanagawa, Kita-gun, Kagawa, Kobe-shi, Hyogo
2025-06-27
Recruiting
GlaxoSmithKline
Phase 1/2
85
Kanagawa, Tokyo
2025-06-12
By invitation
Novo Nordisk A/S
Observational
30
Chiba, Fukui, Fukushima, Hyōgo, Kanagawa, Kawagoe, Miyagi, Nagano
2025-05-02
Recruiting
Hoffmann-La Roche
Phase 3
450
Aichi, Chiba, Fukushima, Hiroshima, Hokkaido, Kanagawa, Okayama, Saitama
2025-04-09
Recruiting
Gilead Sciences
Phase 3
695
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kobe
2025-04-04
Active, closed
cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC
Boston Scientific Corporation
Observational
433
Kamakura-shi, Sendai, Kurashiki-shi, Saitama, Fuchu-shi, Fukuoka-ken, Kanagawa, Kawasaki
2025-03-18
Active, closed
Shockwave Medical, Inc.
Not applicable
81
Asahi, Chiba, Ehime, Fukuoka, Hokkaido, Kanagawa, Miyagi, Nara
2025-03-10
By invitation
Inari Medical
Observational
100
Chuo, Ōta, Kawasaki, Suita, Asahikawa, Chiba, Daitō, Kanagawa
2025-02-17
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Fukuoka, Hiroshima, Kanagawa, Osaka, Tokyo
2025-02-01
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Nagoya, Fukuoka, Asahikawa, Ibaraki, Kagoshima, Sagamihara, Yokohama, Kanagawa
2025-01-08
Recruiting
Novo Nordisk A/S
Phase 2
465
Koriyama-shi, Fukushima, Aichi, Ibaraki, Kanagawa, Kita-ku, Tokyo, Saitama, Sendai-shi, Miyagi, Siga
2024-12-02
Active, closed
Hoffmann-La Roche
Phase 3
400
Chiba, Fukuoka, Gifu, Hyōgo, Kagawa, Kagoshima, Kanagawa, Nagasaki
2024-09-17
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
Chiba, Kanagawa, Nagoya, Osaka, Tokyo
2024-09-12
Recruiting
GlaxoSmithKline
Phase 3
440
Aichi, Fukuoka, Hiroshima, Hokkaido, Kanagawa, Miyagi, Miyazaki, Saitama
2024-09-11
Active, closed
Software as a Medical Device for the Treatment of Patients With PTSD
NCT06589505Post-Traumatic Stress Disorder, PTSD
Otsuka Medical Devices Co., Ltd. Japan
Phase 2/3
52
Yamanashi, Akita, Fukuoka, Gunma, Hokkaido, Hyōgo, Ibaraki, Kanagawa
2024-09-01
Active, closed
Gilead Sciences
Phase 3
640
Chiba, Hyōgo, Kanagawa, Mie, Okayama, Saitama, Shizuoka, Tokyo
2024-08-28
By invitation
Novo Nordisk A/S
Observational
23
Toshima City, Aomori, Fukuoka, Hokkaido, Kagoshima, Kanagawa, Kitakyusyu-shi, Fukuoka, Okinawa
2024-08-08
Active, closed
Incyte Biosciences Japan GK
Phase 3
21
Aichi, Fukui, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kanagawa, Kumamoto
2024-07-30
Active, closed
GlaxoSmithKline
Phase 4
303
Fukuoka, Kanagawa, Miyagi, Osaka, Tokyo
2024-06-06
Active, closed
GlaxoSmithKline
Phase 4
1,358
Fukuoka, Gifu, Hiroshima, Hyōgo, Kagawa, Kagoshima, Kanagawa, Kumamoto
2024-04-16
Recruiting
Zephyr Valve Japan Post-Marketing Surveillance
NCT06332885Emphysema, COPD, Severe Emphysema
Pulmonx Corporation
Observational
140
Aichi, Gifu, Kanagawa, Kanazawa, Kawasaki, Mie, Nagasaki, Nagoya
2024-03-12
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Hidaka, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-cho, Nagoya, Osakasayama-shi, Saitama
2024-02-26
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kanagawa, Kyoto
2023-09-18
Active, closed
Hoffmann-La Roche
Phase 3
687
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hokkaido, Ishikawa, Kanagawa
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Gunma, Hiroshima, Hokkaido, Kanagawa, Miyagi, Shizuoka, Tokushima, Tokyo
2023-09-13
Recruiting
Hoffmann-La Roche
Phase 3
230
Aichi, Chiba, Hiroshima, Kagoshima, Kanagawa, Kyoto, Matsuyama, Saitama
2023-09-08
Active, closed
Cytokinetics
Phase 3
500
Fukuoka, Hyōgo, Ibaraki, Kanagawa, Kochi, Kyoto, Mie, Miyagi
2023-08-31
Recruiting
GlaxoSmithKline
Phase 3
892
Aichi, Chiba, Fukuoka, Hokkaido, Hyōgo, Ibaraki, Kanagawa, Kyoto
2023-08-01
Recruiting
GlaxoSmithKline
Phase 1/2
123
Aomori, Chiba, Kanagawa, Osaka, Tokyo, Yamagata
2023-06-14
Recruiting
Hoffmann-La Roche
Phase 3
100
Chiba, Fukuoka, Kanagawa, Kashiwa-shi, Saitama, Sakaishi
2023-06-01
Active, closed
Servier Affaires Médicales
Phase 3
299
Kanagawa, Kumamoto, Matsuyama, Osaka, Sapporo, Tokyo
2023-05-03
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel
Institut de Recherches Internationales Servier
Phase 1/2
554
Kanagawa, Kyoto, Tokyo
2023-04-18
Active, closed
GlaxoSmithKline
Phase 2
154
Chiba, Kanagawa, Osaka
2023-04-03
Active, closed
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
NCT05567185Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
DrugErdafitinib
Janssen Pharmaceutical K.K.
Phase 1
5
Kanagawa, Osaka, Toyama, Tsukuba
2023-03-03
Active, closed
Daiichi Sankyo
Phase 3
1,170
Ehime, Fukoka, Fukuoka, Hokkaido, Hyōgo, Ishikawa, Kanagawa, Kumamoto
2023-01-11
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Fukui, Fukuoka, Gifu, Hiroshima, Kagawa, Kagoshima, Kanagawa, Nagano
2023-01-02
By invitation
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 2/3
150
Hiroshima, Kanagawa, Osaka, Tokyo
2022-12-28
Recruiting
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Kyoto
2022-12-15
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
100
Ehime, Fukushima, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima, Kanagawa
2022-11-04
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Sapporo, Suita-shi, Aichi, Chiba-shi, Chiba, Gunma, Kanagawa, Osaka, Saitama
2022-11-01
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Bunkyō City, Chiba, Higashiibaraki-gun, Hirakata, Hyôgo, Iruma-gun, Kanagawa, Kanazawa
2022-10-25
Active, closed
GlaxoSmithKline
Phase 2
351
Chiba, Fukuoka, Hyōgo, Kanagawa, Osaka, Saitama
2022-10-14
Active, closed
Gilead Sciences
Phase 3
1,021
Chiba, Ehime, Fukuoka, Hyōgo, Ishikawa, Kanagawa, Miyagi, Niigata
2022-10-12
Active, closed
Hoffmann-La Roche
Phase 3
122
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kanagawa, Miyagi
2022-09-27
Active, closed
Hoffmann-La Roche
Phase 3
139
Chiba, Fukuoka, Fukushima, Hyōgo, Kanagawa, Miyagi, Osaka, Tokyo
2022-08-30
Active, closed
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
NCT06696716Pemphigus, Steroid-resistant Pemphigus
DrugTirabrutinib
Ono Pharmaceutical Co., Ltd.
Phase 3
34
Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hokkaido, Kagoshima, Kanagawa
2022-08-15
Active, closed
GlaxoSmithKline
Phase 3
3,038
Fukuoka, Kanagawa, Tokyo
2022-08-10
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Chūōku, Himeji, Hirakata, Kanagawa, Kurashiki, Kurume, Matsusaka, Niigata
2022-08-05
Active, closed
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
DrugIDRX-42
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1
276
Chiba, Kanagawa, Tokyo
2022-08-03
Active, closed
Genentech, Inc.
Phase 3
373
Aichi, Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kanagawa
2022-08-03
Active, closed
GlaxoSmithKline
Phase 3
163
Kanagawa, Saitama, Tokyo
2022-07-14
Active, closed
Janssen Research & Development, LLC
Phase 2
36
Fukuoka, Fukushima, Kanagawa, Kawachi-Nagano, Matsudo-shi, Matsumoto, Sendai, Tokyo
2022-07-05
Recruiting
Nuvalent Inc.
Phase 1/2
840
Kanagawa, Okayama, Osaka, Shizuoka, Tokyo, Wakayama
2022-06-09
Recruiting
Innovacell GmbH
Phase 3
290
Sapporo, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kumamoto, Kyoto
2022-05-11
Active, closed
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755Moderate Aortic Valve Stenosis
Medtronic Cardiovascular
Not applicable
650
Kanagawa, Isehara, Kawasaki, Osaka
2022-04-27
Active, closed
Novo Nordisk A/S
Phase 3
153
Kanagawa, Saitama
2022-03-24
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Chiba, Fukuoka, Gunma, Hiroshima, Hyōgo, Ishikawa, Kanagawa, Niigata
2022-02-07
Recruiting
Nuvalent Inc.
Phase 1/2
359
Kanagawa, Okayama, Osaka, Shizuoka, Tokyo, Wakayama
2022-01-04
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Gunma, Hyōgo, Kanagawa, Kobe, Kurume, Nagoya, Niigata, Osaka
2021-11-17
Active, closed
argenx
Phase 3
173
Hirakata, Iruma, Kanagawa, Kitakyushu, Shibukawa, Shimotsuke, Tama
2021-11-17
Active, closed
VectivBio AG
Phase 3
158
Kanagawa, Osaka, Sendai, Tokyo
2021-07-13
Active, closed
GlaxoSmithKline
Phase 3
40
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hokkaido, Kagoshima, Kanagawa
2021-06-28
Recruiting
AB122 Platform Study
NCT04999761Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
DrugsPimitespib·Futibatinib·Domvanalimab·Ramucirumab
Taiho Pharmaceutical Co., Ltd.
Phase 1
917
Aichi, Chiba, Ehime, Hokkaido, Kanagawa, Osaka, Shizuoka, Tokyo
2021-06-01
Active, closed
Hoffmann-La Roche
Phase 3
761
Aichi, Chiba, Ehime, Hiroshima, Hokkaido, Ibaraki, Kanagawa, Kyoto
2021-05-03
Active, closed
Hoffmann-La Roche
Phase 3
557
Aichi, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Osaka, Tochigi
2021-04-26
Active, closed
Hoffmann-La Roche
Phase 3
342
Aichi, Chiba, Fukuoka, Hiroshima, Kanagawa, Osaka, Tokyo
2021-03-12
Active, closed
Janssen Research & Development, LLC
Phase 2
220
Iizuka, Kanagawa, Kashihara-shi, Kisarazu-shi, Nagasaki, Osaka, Tokyo, Toyama
2020-12-18
Active, closed
Incyte Biosciences Japan GK
Phase 1/2
72
Aichi, Chiba, Fukui, Fukuoka, Hyōgo, Kanagawa, Kōtoku, Kumamoto-ken
2020-12-15
Active, closed
Janssen Research & Development, LLC
Phase 3
518
Iizuka, Kanagawa, Kashihara, Kawagoe-Shi, Kisarazu-shi, Nagasaki, Osaka, Shūnan
2020-12-07
Active, closed
Hoffmann-La Roche
Phase 3
190
Aichi, Hyōgo, Ishikawa, Kanagawa, Mie, Nagano, Nagasaki, Okayama
2020-09-30
Active, closed
GlaxoSmithKline
Phase 3
242
Chiba, Ehime, Fukui, Gunma, Hiroshima, Hokkaido, Kagawa, Kanagawa
2020-07-14
Active, closed
Actelion
Phase 3
935
Bunkyō City, Fukuoka, Hiroshima, Kagoshima, Kanagawa, Kanazawa, Kobe, Kurume
2020-06-30
Active, closed
GlaxoSmithKline
Phase 3
494
Aichi, Aomori, Ehime, Fukuoka, Gifu, Gunma, Hyōgo, Kanagawa
2020-05-07
Recruiting
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
NCT04559425Heart Block Complete, Heart Block Second Degree
DrugDexamethasone
The Hospital for Sick Children
Observational
350
Kanagawa, Shizuoka
2020-01-01
Active, closed
GlaxoSmithKline
Phase 2
25
Kagoshima, Kanagawa
2019-11-28
Active, closed
Novo Nordisk A/S
Phase 3
134
Aichi, Kagoshima, Kanagawa, Mie, Nara, Saitama, Tokyo
2019-10-21
Active, closed
JCR Pharmaceuticals Co., Ltd.
Phase 2/3
27
Fukui, Fukuoka, Gifu, Hiroshima, Hokkaido, Kanagawa, Kumamoto, Okayama
2019-09-01
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Fukushima, Iruma-gun, Kanagawa, Kitakyusyu-Shi, Kofu, Ōgaki, Sapporo, Sendai
2019-08-15
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
183
Ehime, Fukuoka, Kanagawa, Niigata, Osaka, Sapporo, Shizuoka, Tokyo
2019-07-15
Active, closed
Hoffmann-La Roche
Phase 3
257
Aichi, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kanagawa, Kumamoto
2018-08-16
Active, closed
Biotronik SE & Co. KG
Observational
3,030
Fukuoka, Hiroshima, Kanagawa, Sagamihara, Saitama, Tokyo, Toyoake
2018-05-14
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Bunkyō City, Fukuoka, Hiroshima, Ishikawa, Kanagawa, Kyoto, Matsuyama, Miyagi
2017-09-22
Recruiting
Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)
NCT02781922Hypoplastic Left Heart Syndrome, Single Ventricle
Metcela Inc.
Phase 3
40
Kanagawa, Okayama, Osaka, Shizuoka
2016-06
Rows per page Showing 1–106 of 106
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/kanagawa

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 106 of those studies with a site in Kanagawa.

How many clinical trials are recruiting in Kanagawa?

43 of the 106 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 57 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kanagawa), 106 studies
PhaseStudiesRecruitingShare
Phase 3582154.7%
Phase 216915.1%
Observational837.5%
Phase 1/2766.6%
Phase 1625.7%
Phase 2/3615.7%
Phase 4312.8%
Not applicable201.9%

Most active sponsors

Lead sponsors with the most studies (Kanagawa)
Lead sponsorStudiesRecruiting
GlaxoSmithKline2412
Hoffmann-La Roche165
Novo Nordisk A/S93
Janssen Research & Development, LLC71
Daiichi Sankyo32
Gilead Sciences31
Incyte Biosciences Japan GK20
Nuvalent Inc.22
Ono Pharmaceutical Co., Ltd.21
Pharvaris Netherlands B.V.20
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.